Brian Park, PharmD

Drug Information Specialist https://www.thecardiologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Heart Failure

Istaroxime Granted Fast-Track Designation for Acute Heart Failure

Brian Park, PharmD

August 15, 2019

The FDA has granted Fast Track designation to istaroxime (Windtree Therapeutics) for the treatment of acute heart failure.

Aorta. Coloured 3D CT angiogram of the aorta

Metabolic

Cardiorenal Effects of Sotagliflozin Evaluated in Type 1 Diabetes

Brian Park, PharmD

August 13, 2019

Lexicon Pharmaceuticals announced new data from the phase 3 inTandem1 and inTandem2 studies of sotagliflozin in adult patients with type 1 diabetes.

Heart Failure

Trial Evaluating Sacubitril/Valsartan for HFpEF Misses Primary End Point

Brian Park, PharmD

July 30, 2019

Novartis announced results from the phase 3 PARAGON-HF study evaluating the safety and efficacy of sacubitril/valsartan in HFpEF.

New Guidelines Issued for Management of Atrial Fibrillation

Arrhythmia

FDA to Review Vernakalant for Rapid Conversion of AF in Adults

Brian Park, PharmD

July 29, 2019

The FDA has accepted for review the resubmitted New Drug Application (NDA) for Brinavess (vernakalant hydrochloride; Correvio Pharma) as a treatment for the rapid conversion of adult patients with recent onset atrial fibrillation.

IntelliQuit Mobile App with BioStrip Capture

General Cardiology

IntelliQuit Mobile App Helps Patients, Clinicians Monitor Nicotine Use

Brian Park, PharmD

July 25, 2019

IntelliQuit has announced the release of a mobile app that measures nicotine consumption from any source.

Metabolic

RNAi Therapy for Homozygous FH Receives Orphan Drug Designation

Brian Park, PharmD

July 22, 2019

The FDA has granted Orphan Drug designation to ARO-ANG3 for the treatment of homozygous familial hypercholesterolemia.

General Cardiology

Contrast Agent Gadobutrol Approved for Use in Cardiac MRI

Brian Park, PharmD

July 18, 2019

The FDA has approved Gadavist injection for use in cardiac MRI to assess myocardial perfusion and late gadolinium enhancement in adult patients with known or suspected CAD.

Vascular Medicine

Dabigatran Safe, Effective for Managing VTE in Pediatric Trials

Brian Park, PharmD

July 12, 2019

The open label, randomized, multicenter, phase 2b/3 DIVERSITY trial evaluated the efficacy and safety of dabigatran compared with SOC (low molecular weight heparin or vitamin K antagonist) in 240 children.

General Cardiology

WHO Updates List of Essential Medication for 2019

Brian Park, PharmD

July 12, 2019

The World Health Organization (WHO) has updated the WHO Model List of Essential Medicines for 2019.

Vascular Medicine

FDA Rejects Edsivo NDA for Vascular Ehlers-Danlos Syndrome

Brian Park, PharmD

June 26, 2019

In the CRL, the FDA stated that the Company will need to conduct an adequate and well-controlled trial to evaluate the efficacy of Edsivo in patients with vEDS.

Next post in Vascular Medicine